

ALTERNATIVE TO PTO/SB/08A/B
(Based on PTO 01-08 version)

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/586,037
				Filing Date	(Intl.) January 13, 2005
				First Named Inventor	Jeffrey L. SOUTHARD
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	1	of	3	Attorney Docket Number	560252000800

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	1.	US-4,720,483	01-19-1988	Jansz et al.	
	2.	US-4,764,378	08-16-1988	Keith et al.	
	3.	US-5,023,252	06-11-1991	Hseih	
	4.	US-5,728,396-A	03-17-1998	Peery et al.	
	5.	US-5,958,877-A	09-28-1999	Wimalawansa	
	6.	US-6,358,247-B1	03-19-2002	Altman et al.	
	7.	US-6,809,079-B2	10-26-2004	Southard et al.	
	8.	US-2008/0069865-A1	03-20-2008	Southard et al.	
	9.	US-2008/0097503-A1	04-24-2008	Creaven	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	10.	WO-93/23011-A1	11-25-1993	Minnesota Mining and Manufacturing Company		
	11.	WO-96/30013-A1	10-03-1996	Minnesota Mining and Manufacturing Company		
	12.	WO-03/059250-A2,A3	07-24-2003	Vasogenix Pharmaceuticals, Inc.		
	13.	WO-2005/067890-A2,A3	07-28-2005	Vasogenix Pharmaceuticals, Inc.		
	14.	WO-2005/070444-A2,A3,C1	08-04-2005	Vasogenix Pharmaceuticals, Inc.		
	15.	WO-2005/070445-A2,A3	08-04-2005	Vasogenix Pharmaceuticals, Inc.		
	16.	WO-2006/029320-A1	03-16-2006	Bayer Healthcare LLC		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

ALTERNATIVE TO PTO/SB/08A/B
(Based on PTO 01-08 version)

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/586,037
				Filing Date	(Intl.) January 13, 2005
				First Named Inventor	Jeffrey L. SOUTHARD
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	2	of	3	Attorney Docket Number	560252000800

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	17.	ANAND, I.S. et al. (January 1991). "Cardiovascular and Hormonal Effects of Calcitonin Gene-Related Peptide in Congestive Heart Failure," <i>J. Am. Coll. Cardiol.</i> 17(1):208-217.		
	18.	CHAI, W. et al. (February 15, 2006, e-pub. January 24, 2006). "The Role of Calcitonin Gene-Related Peptide (CGRP) in Ischemic Preconditioning in Isolated Rat Hearts," <i>European Journal of Pharmacology</i> 531(1-3):246-253.		
	19.	FLEISHER, D. et al. (1996). "Improved Oral Drug Delivery: Solubility Limitations Overcome by the Use of Prodrugs," <i>Advanced Drug Delivery Reviews</i> 19:115-130.		
	20.	GENNARI, C. et al. (1990). "Improved Cardiac Performance with Human Calcitonin Gene Related Peptide in Patients with Congestive Heart Failure," <i>Cardiovascular Res.</i> 24(3):239-241.		
	21.	HAEGERSTRAND, A. et al. (May 1990). "Calcitonin Gene-Related Peptide Stimulates Proliferation of Human Endothelial Cells," <i>Proc. Natl. Acad. Sci. USA</i> 87(9):3299-3303.		
	22.	HUNT, S.A. et al. (2001). <u>ACC/AHA Practice Guidelines: ACC/AHA Guidelines for the Evaluation and Management Chronic Heart Failure in the Adult</u> , American College of Cardiology and the American Heart Association, Inc., ed., pp. 1-56.		
	23.	International Search Report mailed on October 5, 2006, for PCT Application No. PCT/US2005/001224, filed on January 13, 2005, five pages.		
	24.	LU, E.-X. et al. (December 1996). "Calcitonin Gene-Related Peptide-Induced Preconditioning Improves Preservation with Cardioplegia," <i>Ann. Thorac. Surg.</i> 62(6):1748-1751.		
	25.	MERRIFIELD, R.B. (1963). "Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide," <i>Journal of the American Chemical Society</i> 85:2149-2154.		
	26.	MERRIFIELD, R.B. (April 18, 1986). "Solid Phase Synthesis," <i>Science</i> 232(4748):341-347.		
	27.	ROBINSON, R.P. et al. (January 5, 1996). "Discovery of the Hemifumarate and (alpha-L-alanyloxy)methyl ether as Prodrugs of an Antirheumatic Oxindole: Prodrugs for the Enolic OH Group," <i>J. Med. Chem</i> 39:10-18.		
	28.	SHEKHAR, Y.C. et al. (April 1, 1991). "Effects of Prolonged Infusion of Human Alpha Calcitonin Gene-Related Peptide on Hemodynamics, Renal Blood Flow and Hormone Levels in Congestive Heart Failure," <i>Am. J. Cardiol.</i> 67(8):732-736.		
	29.	SHIMIZU, K. et al. (December 1999). "Adrenomedullin Receptor Antagonism by Calcitonin Gene-Related Peptide (8-37) Inhibits Carotid Artery Neointimal Hyperplasia after Balloon Injury," <i>Circulation Research</i> 3(17):1199-1205.		
	30.	STEVENSON, R.N. et al. (December 1992). "Calcitonin Gene-Related Peptide: A Haemodynamic Study of a Novel Vasodilator in Patients with Severe Chronic Heart Failure," <i>Intl. J. Cardiol.</i> 37(3):407-414.		
	31.	WIMALAWANSA, S. (October 1996). "Calcitonin Gene-Related Peptide and Its Receptors: Molecular Genetics, Physiology, Pathophysiology, and Therapeutic Potentials," <i>Endocrine Reviews</i> 17(5):533-585.		
	32.	WIMALAWANSA, S. (1997). "Amylin, Calcitonin Gene-Related Peptide, Calcitonin, and Adrenomedullin: A Peptide Superfamily," <i>Critical Reviews in Neurobiology</i> 11(2-3):167-239.		

ALTERNATIVE TO PTO/SB/08A/B
(Based on PTO 01-08 version)

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/586,037
				Filing Date	(Intl.) January 13, 2005
				First Named Inventor	Jeffrey L. SOUTHARD
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	3	of	3	Attorney Docket Number	560252000800

	33.	WOLFRUM, S. et al. (April 15, 2005). "Calcitonin Gene Related Peptide Mediates Cardioprotection by Remote Preconditioning," <i>Regulatory Peptides</i> 127(1-3):217-224.	
	34.	Written Opinion mailed on October 5, 2006, for PCT Application No. PCT/US2005/001224, filed on January 13, 2005, seven pages.	
	35.	ZHOU, Z.-H. et al. (December 2001). "Improvement of Preservation with Cardioplegic Solution by Nitroglycerin-Induced Delayed Preconditioning is Mediated by Calcitonin Gene-Related Peptide," <i>Int. J. Cardiol.</i> 81(2-3):211-218.	

Examiner Signature	/David Romeo/ (12/10/2009)	Date Considered	
-----------------------	----------------------------	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.